Skip to main content
KNSA logo

KNSA · Kiniksa Pharmaceuticals International, plc · Metrics

Track KNSA — free
$93.90 +0.36 (+0.38%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$7.38B
Shares
78.57M
Volume · Nov 20 545.23K Avg daily vol (3M) 658.72K

KNSA metrics

95 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$93.90
Market cap
$7.38B

Price action

23 metrics
Price change (1W)
-2.5%
Price change (30D)
+16.2%
Price change (3M)
+18.8%
Price change (6M)
+76.4%
Price change (YTD)
+127.6%
Price change (1Y)
+126.3%
Trailing year
Price change (5Y)
+669.6%
52-week high
$98.76
52-week low
$37.92
Change from 52-week high
-4.9%
Change from 52-week low
+147.6%
Annualized volatility
56.3%
Annualized volatility (3M)
60.2%
Implied volatility (30D)
50.7%
IV rank (1Y)
19.2
IV percentile (1Y)
43.5
Beta
0.7
RSI (14D)
55.8
Price vs SMA 50
+11.9%
Price vs SMA 200
+46.5%
Avg volume (3M)
658,718
Relative volume
0.8
Average dollar volume
$55.22M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
78.57M

Valuation

12 metrics
P / E (TTM)
71.7
Trailing earnings · reciprocal yield 1.4%
PEG ratio
0.5
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
7.8×
reciprocal yield 12.8%
P / book
10.4
reciprocal yield 9.6%
FCF yield
2.7%
TTM · current market cap
Buyback yield
—
P / FCF
37.4
reciprocal yield 2.7%
P / operating cash flow
37.1
reciprocal yield 2.7%
Earnings yield
1.5%

Historical valuation

8 metrics
P / E historical average (3Y)
176.3×
reciprocal yield 0.6%
P / E historical average (5Y)
119.4×
reciprocal yield 0.8%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-27

Profitability

9 metrics
Gross margin
90.2%
Operating margin
13.8%
Trailing 12 months
Net margin
11.6%
Gross profit (TTM)
$852.89M
Operating profit (TTM)
$130.47M
Net income (TTM)
$109.57M
Trailing 12 months
Diluted EPS (TTM)
$1.31
FCF margin
20.8%
Effective tax rate
25.0%

Per share

11 metrics
Revenue per diluted share (TTM)
$11.36
Gross profit per diluted share (TTM)
$10.24
Operating profit per diluted share (TTM)
$1.56
EBITDA per diluted share (TTM)
$1.58
Net income per diluted share (TTM)
$1.31
Operating cash flow per diluted share (TTM)
$2.39
Free cash flow per diluted share (TTM)
$2.37
Capital expenditures per diluted share (TTM)
$0.02
R&D per diluted share (TTM)
$1.63
Stock compensation per diluted share (TTM)
$0.54
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+58.1%
Year over year
Net income growth YoY
+156.8%
Revenue (TTM)
$945.96M
Trailing 12 months
EPS growth YoY
+143.5%
Shares change YoY
+6.1%
Year over year · more shares
Revenue CAGR (3Y)
+45.5%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
-33.9%
EPS CAGR (5Y)
—
FCF CAGR (3Y)
+188.1%
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
15.4%
Return on assets
11.1%
Debt / equity
—
Current ratio
3.9
EBITDA (TTM)
$132.36M
Free cash flow (TTM)
$197.20M
Quick ratio
3.3
Interest coverage
—
Net debt / EBITDA
-4.3
Return on invested capital
—
Trailing 12 months
Net cash
$568.76M
Latest balance sheet
Cash & equivalents
$81.66M
Total assets
$983.24M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$198.84M
Capital expenditures (TTM)
$1.64M
R&D (TTM)
$135.77M
SG&A (TTM)
$247.15M
Stock compensation (TTM)
$44.99M
R&D / revenue
14.4%
Stock compensation / revenue
4.8%

Ownership (13F)

9 metrics
13F filers
304
13F filer change QoQ
+39
Institutional ownership
60.3%
Conviction holders (share of 13F filers)
2.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+0.8%
Holder tenure
8.0
Price vs estimated holder cost
+89.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
3.9%

Short interest

3 metrics
Short interest
5.5%
Latest settlement · 3.9 days to cover
Days to cover
3.9d
Short-squeeze score
66 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$78.59M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1730430 CUSIP G52694109 13F (30d) 280 filings 272 filers Visit website Investor relations